度洛西汀联合米氮平治疗肺癌化疗患者抑郁的临床研究

目的研究合并抑郁的肺癌化疗患者应用抗抑郁药物干预后的效果及不良反应。方法分别将经我院心理科医师协助诊断为抑郁的肺癌化疗患者90例随机分成4组:度洛西汀组(22例)、米氮平组(23例)、两药联合组(23例)及对照组(22例),均进行化疗4周期,3周为1个疗程,每个疗程化疗前采用《汉密尔顿抑郁量表》(HAMD)进行评分并比较。结果肺癌化疗患者抑郁患病率46.4%,米氮平组、度洛西汀组及两药联用组患者随治疗时间推移抑郁评分均有所减低,差异有统计学意义(P<0.05),且两药联用组抑郁评分均小于同期其他三组,差异有统计学意义(P<0.05)。结论肺癌化疗患者抑郁患病率高,度洛西汀及米氮平均有缓解肺癌患者上述情绪的作用,且两药合用效果更显著。

Research on the treatment of duloxetine combined with mirtazapine for lung cancer patients with depression

Objective To investigate the efficacy and safety of antidepressant drug treatment for lung cancer patients with depression.Methods 90 lung cancer patients who needed chemotherapy and diagnosed depression by psychiatrist were randomly divided into four groups：duloxetine group （n =22）,mirtazapine group （n =23）,combination group （n =23） and control group （n =22）.All patients received 4 cycles of chemotherapy,three weeks for a cycle.The depression state of the lung cancer patients was assessed by the Hamilton Depression Rating Scale（HAMD） before each chemotherapy cycle.Results The prevalence of the depression was 46.3％ in the lung cancer patients who needed chemotherapy.The HAMD scores of psychiatric drug treatment groups decreased with the treatment,with statistical sig nificance（P ＜ 0.05）.Combination group was lower than the other three groups,with statistical significance （P ＜0.05）.Conclusion The prevalence of the depression is high in patients with lung cancer who need chemotherapy.Both duloxetine and mirtazapine can ease depression emotion,and the combination of the two drugs is more effective.